A carregar...
Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer
OBJECTIVE: Nivolumab is a fully human IgG4 programmed cell death 1 immune checkpoint inhibitor monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the safety and efficacy of nivolumab in Japanese patients with advanced or recurr...
Na minha lista:
Publicado no: | ESMO Open |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BMJ Publishing Group
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5566979/ https://ncbi.nlm.nih.gov/pubmed/28861280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2016-000108 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|